Perinatal Reduced Blood Concentrations of Free Carnitine and Acylcarnitines in Infants with Cystic Fibrosis

Am J Perinatol. 2021 Jul;38(8):828-833. doi: 10.1055/s-0039-3402723. Epub 2019 Dec 31.

Abstract

Objective: Cystic fibrosis (CF) is a multisystemic inherited disease. The aim of this study was to determine free carnitine (FC) and acylcarnitine concentrations in CF newborns with various mutations of the CFTR gene perinatally.

Study design: FC/acylcarnitines were determined in dried blood spots via liquid chromatography-tandem mass spectrometry (LC-MS/MS) on the third day of life of full-term normal (n = 50) and CF (n = 28) newborns. For infants with elevated immunoreactive trypsinogen values, FC/acylcarnitines were quantified again 48 hours later, followed by mutational analysis of CFTR gene via Sanger sequencing.

Results: Initial FC and sums of acylcarnitine concentrations were statistically significantly lower in CF patients than in controls and even lower 48 hours later. The mutations F508del and 621 + 1G > T were predominantly identified among CF patients.

Conclusion: Low FC and acylcarnitine concentrations were measured perinatally in CF patients, for all CFTR mutations detected. Carnitine supplementation of breastfeeding mothers could be beneficial.

MeSH terms

  • Biomarkers
  • Carnitine / administration & dosage
  • Carnitine / analogs & derivatives*
  • Carnitine / blood*
  • Cystic Fibrosis / blood*
  • Cystic Fibrosis / genetics
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • DNA Mutational Analysis
  • Food, Fortified
  • Humans
  • Infant, Newborn
  • Milk, Human
  • Mutation
  • Neonatal Screening

Substances

  • Biomarkers
  • CFTR protein, human
  • acylcarnitine
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Carnitine